{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:59Z","timestamp":1789603859355,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172257"],"award-info":[{"award-number":["82172257"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key areas of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1111030005"],"award-info":[{"award-number":["2023B1111030005"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2022YFC2303600"],"award-info":[{"award-number":["2022YFC2303600"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jve.2025.100616","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:19:25Z","timestamp":1763651965000},"page":"100616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and predictors of pegylated-interferon in hepatitis B surface antigen seroclearance in immune active and inactive chronic hepatitis B patients"],"prefix":"10.1016","volume":"11","author":[{"given":"Chao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-3589","authenticated-orcid":false,"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jve.2025.100616_bib1","first-page":"1425","article-title":"Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jve.2025.100616_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jve.2025.100616_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a functional cure for hepatitis B","volume":"18","author":"Lok","year":"2024","journal-title":"Gut Liver"},{"key":"10.1016\/j.jve.2025.100616_bib4","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jve.2025.100616_bib5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jve.2025.100616_bib6","first-page":"515","article-title":"The concept of a fountional cure for hepatitis B keeps pace with the times","volume":"33","author":"Liu","year":"2025","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.jve.2025.100616_bib7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jve.2025.100616_bib8","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1136\/gutjnl-2024-332182","article-title":"High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy","volume":"73","author":"Fan","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jve.2025.100616_bib9","doi-asserted-by":"crossref","first-page":"1332232","DOI":"10.3389\/fcimb.2023.1332232","article-title":"Clinical cure induced by pegylated interferon \u03b1-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study","volume":"13","author":"Wen","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jve.2025.100616_bib10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jve.2025.100616_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jve.2025.100616_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jve.2025.100616_bib13","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/liv.14897","article-title":"Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers","volume":"41","author":"Wu","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jve.2025.100616_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jve.2025.100616_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jve.2025.100616_bib16","doi-asserted-by":"crossref","first-page":"1257113","DOI":"10.3389\/fimmu.2023.1257113","article-title":"Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8(+) T cell quality","volume":"14","author":"Takahama","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jve.2025.100616_bib17","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/jvh.13599","article-title":"Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials","volume":"28","author":"De Ridder","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jve.2025.100616_bib18","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/gut.2004.062208","article-title":"Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon alpha-2b therapy","volume":"54","author":"Flink","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jve.2025.100616_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jve.2025.100616_bib20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/jmv.21778","article-title":"Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment","volume":"82","author":"Hansen","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.jve.2025.100616_bib21","doi-asserted-by":"crossref","first-page":"15658","DOI":"10.1038\/s41598-017-15594-0","article-title":"Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jve.2025.100616_bib22","first-page":"52","article-title":"Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia1919","volume":"40","author":"Wu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.jve.2025.100616_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/jvh.13613","article-title":"Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection","volume":"28","author":"Choi","year":"2021","journal-title":"J Viral Hepat"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664025000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664025000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:44:03Z","timestamp":1773927843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664025000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2055664025000354"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2025.100616","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and predictors of pegylated-interferon in hepatitis B surface antigen seroclearance in immune active and inactive chronic hepatitis B patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2025.100616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100616"}}